AtriCure (NASDAQ:ATRC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AtriCure (NASDAQ:ATRC – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

ATRC has been the subject of a number of other research reports. UBS Group downgraded AtriCure from a “buy” rating to a “sell” rating in a report on Wednesday, October 21st. JPMorgan Chase & Co. boosted their target price on shares of AtriCure from $36.00 to $62.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Wednesday, October 21st. Canaccord Genuity Group upped their target price on shares of AtriCure from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Finally, Raymond James Financial set a $52.00 price target on shares of AtriCure in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and a consensus target price of $62.30.

Check Out Our Latest Analysis on ATRC

AtriCure Stock Down 2.7%

Shares of NASDAQ:ATRC opened at $55.31 on Friday. AtriCure has a 52-week low of $25.36 and a 52-week high of $66.02. The firm has a market capitalization of $2.82 billion, a P/E ratio of 136.54 and a beta of 1.23. The stock has a 50 day moving average price of $57.56 and a 200-day moving average price of $39.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.29 and a current ratio of 4.33.

AtriCure (NASDAQ:ATRC – Get Free Report) last released its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. The company had revenue of $154.45 million during the quarter, compared to analysts’ expectations of $151.05 million. As a group, equities research analysts anticipate that AtriCure will post 0.44 EPS for the current fiscal year.

Insider Transactions at AtriCure

In related news, insider Karl S. Dahlquist sold 9,370 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the transaction, the insider owned 87,319 shares of the company’s stock, valued at $4,269,025.91. This trade represents a 9.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Regina E. Groves sold 5,313 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the transaction, the director directly owned 34,546 shares of the company’s stock, valued at approximately $1,873,084.12. This trade represents a 13.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 39,026 shares of company stock valued at $2,172,263 in the last ninety days. 4.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AtriCure

Several hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC grew its stake in shares of AtriCure by 25.5% in the third quarter. Global Retirement Partners LLC now owns 2,352 shares of the medical device company’s stock worth $132,000 after acquiring an additional 478 shares during the last quarter. Allworth Financial LP increased its holdings in shares of AtriCure by 54.5% during the third quarter. Allworth Financial LP now owns 2,359 shares of the medical device company’s stock valued at $133,000 after acquiring an additional 832 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of AtriCure by 4.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 22,808 shares of the medical device company’s stock worth $1,282,000 after purchasing an additional 900 shares during the last quarter. Harbor Investment Advisory LLC purchased a new position in shares of AtriCure in the 2nd quarter worth about $40,000. Finally, Sterling Capital Management LLC raised its position in shares of AtriCure by 841.1% in the 3rd quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock worth $93,000 after purchasing an additional 1,472 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

About AtriCure

(Get Free Report)

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.

Further Reading

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.